Sweden
NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
18 September 2023
In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel,…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…
International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
1 May 2015
The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight…
Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
1 November 2009
This study compares pricing and reimbursement (P&R) policy for 43 orphan medicinal products (OMPs) across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden…